News
News
- Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment
08/13/2019 / 14:15 - GlobeNewswire - Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production
07/24/2019 / 14:30 - GlobeNewswire - Novan SB206 Phase 3 Molluscum Pivotal Program Update
07/11/2019 / 14:15 - GlobeNewswire - Novan Expands External Business Partner Network
06/19/2019 / 14:15 - GlobeNewswire - Novan to Participate in JMP Securities Life Sciences Conference
06/13/2019 / 15:15 - GlobeNewswire - Novan Achieves Compliance with Nasdaq Listing Rule 5450(b)(2)(A)
06/06/2019 / 22:15 - GlobeNewswire - First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program
06/04/2019 / 12:30 - GlobeNewswire - Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019
05/31/2019 / 22:15 - GlobeNewswire - Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
05/07/2019 / 22:15 - GlobeNewswire - Novan Completes Funding Transaction with Ligand Pharmaceuticals
05/06/2019 / 15:00 - GlobeNewswire
Real-time